CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

nasopharyngeal swabWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug2982 rectal swab Wiki 0.71
drug2997 serology test Wiki 0.71
drug2992 saliva sample Wiki 0.71
drug1550 NG Biotech Wiki 0.71

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D004630 Emergencies NIH 0.14
D014777 Virus Diseases NIH 0.09
D007239 Infection NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials

1 Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France

Arriving in December 2019, Coronavirus COVID-19 infection is causing a global pandemic with high morbidity and mortality among adults and especially seniors. The child appears little or no affected by this infection. It is estimated that the child could be asymptomatic or pauci-symptomatic carrier and thus be vector of the disease. For this reason, measures have been taken to close schools and contain populations in a large number of countries, including France. However, there are no data on the prevalence of COVID-19 in children.

NCT04336761 Coronavirus COVID Infection Viral Diagnostic Test: nasopharyngeal swab
MeSH:Emergencies Virus Diseases

Primary Outcomes

Measure: Prevalence of positivity of COVID-19 virus measured by rt-PCR

Time: At 28 days

Secondary Outcomes

Description: children admitted to pediatric emergencies for respiratory signs Children hospitalized as a result of travelling to pediatric emergency departments for respiratory signs Respiratory asymptomatic children admitted to pediatric emergencies

Measure: Prevalence of positivity of COVID-19 virus measured by rt-PCR in the following subpopulations of emergency patients

Time: at the end an average 28 days

Measure: Respiratory signs of children tested within 28 day

Time: through study completion, an average 28 days

Measure: Percentage of children hospitalized tested within 28 day

Time: through study completion, an average 28 days

Description: the degree of relationship with these contacts and the time spent in contact with them within 24 hours before emergency

Measure: Contact frequency

Time: At inclusion

Measure: Prevalence of positivity of other respiratory viruses measured by rt-PCR

Time: at 28 days

2 Seroprevalence and Antibody Profiling Against SARS-CoV2 in Children and Their Parents

The purpose of this study is to provide weekly data on the proportion of seroconverted children in the Parisian area and their immune status. It will also provide insight into the number of children currently infected at each time point including healthy carriers. Investigators will provide similar data on their parents in an ancillary study.

NCT04355533 COVID-19 Infection Biological: serology test Diagnostic Test: NG Biotech Biological: nasopharyngeal swab Biological: rectal swab Biological: saliva sample
MeSH:Infection

Primary Outcomes

Description: serology

Measure: Seroconversion against SARS-CoV2 in children of the Parisian area

Time: at inclusion

Secondary Outcomes

Description: Serology, measure of Ab in children

Measure: Protective immunity

Time: at inclusion

Description: Serology in children

Measure: Measure of Ab antiN and Ab anti-S1

Time: at inclusion

Description: Serology in children

Measure: Neutralization activity

Time: at inclusion

Description: in children, qualitative and quantitative measure , in nasopharynx, saliva and stool

Measure: Positive qPCR

Time: at inclusion

Description: in children, qualitative and quantitative measure , in nasopharynx, saliva and stool

Measure: correlation between different Ab and qPCR and neutralization activity

Time: at inclusion

Description: in children

Measure: correlation of the NGBiotech rapid test with the classical serological result

Time: at inclusion

Description: in children, PCR results in nasopharynx, saliva and stool

Measure: correlation of the NGBiotech rapid test with qPCR results

Time: at inclusion

Description: Serology, measure of Ab in PCR positive children

Measure: Protective immunity

Time: Day 7

Description: Serology, measure of Ab in PCR positive children

Measure: Protective immunity

Time: Day 15

Description: Serology, measure of Ab in PCR positive children

Measure: Protective immunity

Time: Day 30

Description: Serology, measure of Ab in PCR positive children

Measure: Protective immunity

Time: At 6 months

Description: Serology, measure of Ab in PCR positive children

Measure: Protective immunity

Time: At 12 months

Description: Sars-Cov2 PCR in PCR positive children

Measure: duration of viral carriage in stool, saliva and or nasopharynx

Time: until 30 days post onset

Description: Serology in PCR positive children

Measure: correlation between antibody profile and viral clearance

Time: until 30 days post onset

Description: Immune cells in positive PCR children

Measure: Ab profile and memory of immunity

Time: At Day 7

Description: Immune cells in positive PCR children

Measure: Ab profile and memory of immunity

Time: At Day 15

Description: Immune cells in positive PCR children

Measure: Ab profile and memory of immunity

Time: At Day 30

Description: Immune cells in positive PCR children

Measure: Ab profile and memory of immunity

Time: At 6 months

Description: Immune cells in positive PCR children

Measure: Ab profile and memory of immunity

Time: At 12 months

Description: viral content (qPCR and immunodetection); presence of IgG, M, and A

Measure: saliva biofluid characteristics of COVID-19 infected

Time: Until 1 year of follow-up

Description: in positive PCR children

Measure: correlation of LIPS, the NGBiotech rapid test with the classical serological result

Time: Until 12 months of follow-up

Description: Clinical examination and questioning in positive PCR children

Measure: Presence of COVID-19 Symptom

Time: Until 12 months of follow-up

Description: Ancillary study: Serology in parents

Measure: seroconversion against SARS-CoV2 in parents of the Parisian area

Time: at inclusion

Description: Ancillary study: Serology in parents

Measure: Intra-family correlation of serological results

Time: Until 12 months of follow-up

Description: Ancillary study: Serology in parents

Measure: Measure of Ab antiN and Ab anti-S1 and neutralization activity

Time: at inclusion

Description: Ancillary study: Serology in parents

Measure: correlation of the NGBiotech rapid test with the classical serological result

Time: at inclusion

Description: Ancillary study: in parents, qualitative and quantitative measure , in nasopharynx, saliva

Measure: Positive qPCR

Time: at inclusion

Description: Ancillary study: in parents, qualitative and quantitative measure , in nasopharynx, saliva, Ab anti-N, Ab anti-S1, neutralization serum

Measure: correlation between different Ab and qPCR

Time: at inclusion

Description: Ancillary study: Serology in PCR positive parents

Measure: correlation between antibody profile and viral clearance

Time: until 30 days post onset

Description: Ancillary study: Immune cells in positive PCR parents

Measure: Ab profile and memory of immunity

Time: at Day 7

Description: Ancillary study: Immune cells in positive PCR parents

Measure: Ab profile and memory of immunity

Time: at Day 15

Description: Ancillary study: Immune cells in positive PCR parents

Measure: Ab profile and memory of immunity

Time: at Day 30

Description: Ancillary study: Immune cells in positive PCR parents

Measure: Ab profile and memory of immunity

Time: at 6 months

Description: Ancillary study: Immune cells in positive PCR parents

Measure: Ab profile and memory of immunity

Time: at 12 months

No related HPO nodes (Using clinical trials)